Published in Vaccine Weekly, April 4th, 2001
M. Ledwith noted that the pressure to develop an effective pneumococcal vaccine has intensified, thanks growing antibiotic resistance and the lack of efficacy and long-term immunity conferred by the purified polysaccharide vaccine.
The vaccine was particularly inadequate for children younger than two, the age group most likely to be affected by Pneumococcus, Ledwith noted...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.